Aldeyra Therapeutics, Inc.
ALDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $230 | $344 | $297 |
| - Cash | $59 | $41 | $50 | $55 |
| + Debt | $0 | $16 | $16 | $15 |
| Enterprise Value | – | $204 | $310 | $258 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$7 | -$9 | -$9 | -$15 |
| % Margin | – | – | – | – |
| Net Income | -$8 | -$10 | -$10 | -$16 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.13 | -0.16 | -0.17 | -0.27 |
| % Growth | 18.8% | 5.9% | 37% | – |
| Operating Cash Flow | -$7 | -$9 | -$12 | -$12 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$7 | -$9 | -$12 | -$12 |